This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
IL3RA · Western blot design guide
IL3RA Western Blot Planning Guide
Plan a IL3RA Western blot around the catalog-observed 43.3 kDa band, image-backed A04307 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
IL3RA Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 43.3 kDa observed | |
| Observed band | 43.3 kDa observed | |
| Gel | 12-15% | |
| Positive control | Fallopian tube | |
| Negative control | Hippocampus |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 43.3 kDa |
| ⓘ | Localization | Cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated IL3RA Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Cerebral cortex |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A04307 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected IL3RA Western Blot Band Size?
Use the product-observed 43.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 43.3 kDa | Matches the authoritative product WB observation. |
| 43.3 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected IL3RA appearancePlan around 43.3 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 43.3 kDa; use this as the primary experimental expectation. |
| Calculated mass | 43.3 kDa from UniProt P26951; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A04307. |
| Situation | Likely cause | Next action |
|---|---|---|
| 43.3 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing IL3RA band
A04307 · IL3RA
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for IL3RA Western blot
🧪Use Fallopian tube as the first positive-control candidate and retain an orthogonal negative control.
Positive control: Fallopian tube (High)
Negative control: Hippocampus (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for IL3RA
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Fallopian tube | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebral cortex | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adipose tissue | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced IL3RA Western Blot Tips
Deeper troubleshooting and optimisation questions for IL3RA, answered from its protein features.
Which band should guide the blot?
Use 43.3 kDa, the observation attached to the authoritative A04307 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 43.3 kDa expectation.
Which positive control should I start with?
Start with Fallopian tube, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Hippocampus as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for IL3RA Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A04307 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
IL3RA Western Blot Reagents
Human-reactive IL3RA Western blot reagents with authoritative product imagery.
Real WB data
Anti-IL3RA/CD123 Antibody Picoband®
Cat # A04307
Real WB data
Anti-IL3RA Antibody Picoband®
Cat # PA1617
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P26951
- Human Protein Atlas — IL3RA
- A04307 product record
- PMC11067302 — E3 ubiquitin ligase RNF128 negatively regulates the IL-3/STAT5 signaling pathway by facilitating K27-linked polyubiquitination of IL-3Rα (Cell communication and signaling : CCS, 2024)
- PMC10986138 — EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia (Cell communication and signaling : CCS, 2024)